Oncotarget

Research Papers:

Long non-coding RNA UCA1 induces non-T790M acquired resistance to EGFR-TKIs by activating the AKT/mTOR pathway in EGFR-mutant non-small cell lung cancer

Ningning Cheng, Weijing Cai, Shengxiang Ren, Xuefei Li, Qi Wang, Hui Pan, Mingchuan Zhao, Jiayu Li, Yishi Zhang, Chao Zhao, Xiaoxia Chen, Ke Fei, Caicun Zhou _ and Fred R. Hirsch

PDF  |  HTML  |  Supplementary Files  |  How to cite

Oncotarget. 2015; 6:23582-23593. https://doi.org/10.18632/oncotarget.4361

Metrics: PDF 5506 views  |   HTML 3153 views  |   ?  


Abstract

Ningning Cheng1,*, Weijing Cai1,*, Shengxiang Ren1, Xuefei Li2, Qi Wang1, Hui Pan1, Mingchuan Zhao1, Jiayu Li1, Yishi Zhang1, Chao Zhao2, Xiaoxia Chen1, Ke Fei3, Caicun Zhou1 and Fred R. Hirsch4

1 Department of Medical Oncology, Shanghai Pulmonary Hospital, Tongji University, Tongji University Medical School Cancer Institute, Shanghai, P. R. China

2 Department of Lung Cancer and Immunology, Shanghai Pulmonary Hospital, Tongji University, Tongji University Medical School Cancer Institute, Shanghai, P. R. China

3 Department of Thoracic Surgery, Shanghai Pulmonary Hospital, Tongji University, Tongji University Medical School Cancer Institute, Shanghai, P. R. China

4 Department of Medical and Pathology, University of Colorado Cancer Center, Aurora, Colorado, USA

* These authors have contributed equally to this work

Correspondence to:

Caicun Zhou, email:

Keywords: UCA1, EGFR-TKIs, acquired resistance, non-small cell lung cancer

Received: February 09, 2015 Accepted: June 01, 2015 Published: June 08, 2015

Abstract

The aim of this study was to explore the role of long non-coding RNA UCA1 (urothelial cancer-associated 1) in acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) in EGFR-mutant non-small cell lung cancer (NSCLC). In our study, UCA1 expression was significantly increased in lung cancer cells and patients with acquired resistance to EGFR-TKIs. Over-expression of UCA1 was significantly associated with a shorter progression-free survival (PFS) [13.0 vs. 8.5 months, P < 0.01] in tumors with respond to EGFR-TKIs. The significant relationship was not observed in patients with T790M mutation (10.5 vs. 12.0 months, P = 0.778), but in patients with non-T790M (19.0 vs. 9.0 months, P = 0.023). UCA1 knockdown restored gefitinib sensitivity in acquired resistant cells with non-T790M and inhibited the activation of the AKT/mTOR pathway and epithelial-mesenchymal transition (EMT). The mTOR inhibitor was effective in UCA1-expressing cell PC9/R. Inhibiting mTOR could change the expression of UCA1, although there was no significant difference. In conclusion, the influence of over-expression of UCA1 on PFS for patients with acquired resistance to EGFR-TKIs was from the subgroup with non-T790M mutation. UCA1 may induce non-T790M acquired resistance to EGFR-TKIs by activating the AKT/mTOR pathway and EMT.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 4361